Medication discontinuation

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
수요일, 3월 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

Retrieved on: 
월요일, 12월 11, 2023
Psychiatry, Quality of life, Medication discontinuation, GEMINI, Evolve, Depression, University, DSM-IV codes, Therapy, Drug, Quality, FRCPC, Annual general meeting, CNS, American College, University of Toronto, EVOLVE, Central nervous system, MDD, Anxiety, Grammatical mood, ASCEND, Pharmaceutical industry

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD). These new data were presented at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting, held in Tampa, Florida, from Dec. 3-6, 2023.

Key Points: 
  • New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode
    NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD).
  • These new data were presented at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting, held in Tampa, Florida, from Dec. 3-6, 2023.
  • An evaluation of interest and activity levels of individuals with MDD following treatment with Auvelity in a pooled post-hoc analysis of the placebo-controlled GEMINI and active-controlled ASCEND studies, and an analysis of potential withdrawal symptoms following discontinuation of Auvelity treatment in the GEMINI trial were also presented.
  • “Depression exacts an extraordinary impact on affected individuals especially by impairing enjoyment in activities and role function,” said Roger McIntyre, MD, FRCPC, Professor of Psychiatry and Pharmacology at the University of Toronto and lead author.

Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting

Retrieved on: 
목요일, 11월 2, 2023
Eli Lilly and Company, Experiment, NYSE, Reversibility, Prior, SLL, Use, LLY, Safety, Chronic lymphocytic leukemia, Mantle cell lymphoma, Covalent bond, Medication discontinuation, Society, ASH, Lymphocytosis, Tyrosine kinase, CLL, Poster, MCL, Lymphoid leukemia, Therapy, BTK, Manchester Grand Hyatt Hotel, Pharmaceutical industry, Vaccine, Hotel, Patient

INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.

Key Points: 
  • INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.
  • The presentations will provide updated, longer follow-up clinical safety and efficacy data for approved and investigational uses of pirtobrutinib from the ongoing Phase 1/2 BRUIN study in multiple B-cell malignancies.
  • In mantle cell lymphoma (MCL), an oral presentation will provide updated safety and efficacy results of pirtobrutinib in all patients, including those with biologically high-risk relapsed or refractory MCL.
  • Additionally, poster presentations will provide data on the clinical impact of pirtobrutinib following cBTKi treatment across other B-cell malignancies.

Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV

Retrieved on: 
화요일, 9월 12, 2023
Gabapentinoid, PALO, Mid America Heart Institute, Aes, Medical director, MD, Patient, Medication discontinuation, Neuropathic pain, OTC, FDA Adverse Event Reporting System, Patient satisfaction, Multimodal, Therapy, Chronic pain, Conference, Treatment, Dietary supplement, Nursing, Lidocaine

PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual PAINWeek Conference on the benefits of ZTlido (lidocaine topical system).

Key Points: 
  • PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual PAINWeek Conference on the benefits of ZTlido (lidocaine topical system).
  • The conference was held from September 5-8, 2023 in Las Vegas, NV.
  • Impact of Adhesion on Patient Satisfaction, Medication Switching and Discontinuation with Lidocaine Topical Patches Based on FDA Adverse Event Reporting and Patient Surveys.
  • “More new data presented to support superior adhesion qualities of ZTLido, as well as decreased healthcare resource utilization compared to Lidocaine 5% patch demonstrating significant reduction in outpatient visits and ER/Urgent Care visits.

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Retrieved on: 
화요일, 5월 30, 2023
Presenteeism, Major depressive disorder, Central nervous system, Solriamfetol, Obstructive sleep apnea, Somnolence, State University of New York Upstate Medical University, EDS, Narcolepsy, Disability, Functional disorder, OSA, CNS, ASCP, Drug, MDD, MD, Patient, Domain, Ontario Prehospital Advanced Life Support Studies, Randomness, Medication discontinuation, Annual general meeting, Magnetic resonance, United, Therapy, SHARP, Society, Dextromethorphan/bupropion, Cognitive deficit, Pharmaceutical industry, Medical device, Apnea

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Auvelity® (dextromethorphan-bupropion), Sunosi® (solriamfetol), and disease state at the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held from May 30-June 3 in Miami. The presentations on Auvelity incorporate new data and post-hoc analyses including demonstration of functional improvement in patients with major depressive disorder (MDD). The presentations on Sunosi include data from the SHARP (Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled) study demonstrating improvement in cognitive function in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA).

Key Points: 
  • NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Auvelity® (dextromethorphan-bupropion), Sunosi® (solriamfetol), and disease state at the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held from May 30-June 3 in Miami.
  • The presentations on Auvelity incorporate new data and post-hoc analyses including demonstration of functional improvement in patients with major depressive disorder (MDD).
  • The presentations on Sunosi include data from the SHARP (Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled) study demonstrating improvement in cognitive function in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA).
  • “MDD is the leading cause of disability worldwide and improvement in functioning is critically important to people with MDD.

FRO – Special General Meeting Approves the Redomiciliation of Frontline to Cyprus

Retrieved on: 
화요일, 12월 20, 2022
Oslo Stock Exchange, LEI, Corporate law, Memorandum, CUSIP, European, Cyprus Securities and Exchange Commission, Proxy, FRO, Security (finance), Person, Medication discontinuation, Special, ISIN, Mass meeting, Restatements of the Law, Acquisition, Prospectus, Registrar, NYSE, Frontline Ltd., Sale, Council, Republic, PricewaterhouseCoopers, European Parliament, Official receiver, Risk management, Copper, Front line (disambiguation), EU

As will follow from these resolutions, Frontline’s shareholders have approved the Redomiciliation of the Company to the Republic of Cyprus under the name of Frontline plc.

Key Points: 
  • As will follow from these resolutions, Frontline’s shareholders have approved the Redomiciliation of the Company to the Republic of Cyprus under the name of Frontline plc.
  • Following the effective date of the Redomiciliation, shareholders of Frontline will hold one share of Frontline plc for each ordinary share of Frontline held prior to the Redomiciliation.
  • Upon effectiveness of the Redomiciliation, the rights of shareholders of Frontline plc will arise under Cyprus law and the Amended and Restated Memorandum and Articles of Association (the “Frontline Cyprus Charter”).
  • The Frontline Cyprus Charter, as approved at the Special General Meeting, will be effective from the date the Temporary Redomiciliation Certificate is issued by the Cyprus Companies' Registry.

FHLBank San Francisco to Discontinue Publishing Cost of Funds Indices in Early 2022

Retrieved on: 
수요일, 9월 8, 2021

SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- As previously announced, the Federal Home Loan Bank of San Francisco is discontinuing its cost of funds indices in early 2022.

Key Points: 
  • SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- As previously announced, the Federal Home Loan Bank of San Francisco is discontinuing its cost of funds indices in early 2022.
  • The Bank will continue publishing the 11th District Monthly Weighted Average Cost of Funds Index (COFI) until the announcement of the December 2021 COFI in January 2022.
  • The Bank will also continue publishing the Semiannual Weighted Average Cost of Funds Indices for the 11th District and for California until the announcement of the July-December 2021 indices in February 2022.
  • UCLA Anderson Forecast published their study, Consequences of the Discontinuation of the Eleventh District Cost of Funds Index, in April 2019.

Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia

Retrieved on: 
월요일, 4월 26, 2021
Psychopathology, Psychosis, Schizophrenia, Health care, Medication discontinuation, Health sciences, Health

The drug candidate also met all safety endpoints including clinical, labs, body weight, prolactin, lipids, fasting glucose, and EKG.

Key Points: 
  • The drug candidate also met all safety endpoints including clinical, labs, body weight, prolactin, lipids, fasting glucose, and EKG.
  • Brilaroxazine also mitigated positive symptoms and negative symptoms, and improved social functioning and cognition.
  • We are very excited about our promising phase 2 clinical data and the potential for our drug candidate to address major unmet needs associated with current treatments.\xe2\x80\x9d\nDr.
  • Moreover, we estimate discontinuation/non-compliance rates at 30 to 45% in the acute phase treatment and up to 74% in the long-term treatment of stable schizophrenia patients.

CHESS Health Selected for Nationwide NIDA Study on Medication for Opioid Use Disorder

Retrieved on: 
목요일, 7월 23, 2020
Health, Articles, Clinical pharmacology, Adherence, Health care quality, Medical terminology, Pharmacy, Medication discontinuation

Patients stable on medication and who wish to taper and, ultimately, discontinue medication will be randomized to receive CHESS' evidence-based Connections App plus medical management or medical management alone.

Key Points: 
  • Patients stable on medication and who wish to taper and, ultimately, discontinue medication will be randomized to receive CHESS' evidence-based Connections App plus medical management or medical management alone.
  • The study will measure the difference in successful discontinuation from medication without relapse to opioid use with and without the Connections App.
  • "This national study is incredibly important in testing strategies for medication adherence and discontinuation," said Hans Morefield, chief executive officer of CHESS Health.
  • We are thrilled that CHESS Health has partnered with us to provide their innovative eRecovery app to our participants."

Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference

Retrieved on: 
금요일, 10월 18, 2019
Drugs, Medicine, RTT, Health, Clinical pharmacology, Pharmaceuticals policy, Molluscum contagiosum, Poxviruses, Medication discontinuation, Medroxyprogesterone acetate

These data are being presented in poster form at the 2019 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV.

Key Points: 
  • These data are being presented in poster form at the 2019 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV.
  • Rates of discontinuation of study medication due to an adverse event were low (1.9% for VP-102; 0.5% for vehicle).
  • Following positive topline results from two pivotal Phase 3 trials, the Company submitted an NDA in September 2019 for VP-102 for the treatment of molluscum.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.